The Risk of SARS-CoV-2 Infection in Pregnant Women: An Observational Cohort Study Using the BIFAP Database.
SARS-CoV-2
cohort study
incidence rates
pregnancy
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
02 Dec 2022
02 Dec 2022
Historique:
received:
03
11
2022
revised:
21
11
2022
accepted:
28
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
It has been suggested that women experiencing during pregnancy several physiological and immunological changes that might increase the risk of any infection including the SARS-CoV-2. We aimed to quantify the risk of SARS-CoV-2 infection during pregnancy compared with women with no pregnancies. We used data from the BIFAP database and a published algorithm to identify all pregnancies during 2020. Pregnancies were matched (1:4) by age region, and length of pregnancy with a cohort of women of childbearing age. All women with SARS-CoV-2 infection before entering the study were discarded. We estimated incidence rates of SARS-CoV-2 with 95% confidence intervals (CIs) expressed by 1000 person-months as well as Kaplan-Meier figures overall and also stratified according to pregnancy period: during pregnancy, at puerperium (from end of pregnancy up to 42 days) and after pregnancy. (from 43 days after pregnancy up to end pf study period (i.e., June 2021). We conducted a Cox regression to assess risk factors for SARS-COV infection. The incidence rate of SARS-CoV-2 infection expressed by 1000 person-months were. There was a total of 103,185 pregnancies and 412,740 matched women at childbearing, with a mean age of 32.3 years. The corresponding incidence rates of SARS-CoV-2 infection according to cohorts were: 2.44 cases per 1000 person-months (confidence interval (CI) 95%: 2.40-2.50) and 4.29 (95% CI: 4.15-4.43) for comparison cohort. The incidence rate ratio (IRR) of SARS-CoV-2 was 1.76 (95% CI: 1.69-1.83). When analyzing according to pregnancy period, the IRRs were 1.30 (95% CI: 11.20-1.41) during the puerperium and 1.19 (95% CI: 41.15-1.23) after pregnancy. In addition to pregnancy itself, other important risk factors were obesity (1.33 (95% CI: 1.23-1.44)) and diabetes (1.23 (95% CI: 11.00-1.50). Pregnant women are at increased risk of SARS-CoV-2 infection compared with women of childbearing age not pregnant. Nevertheless, there is a trend towards reverting during puerperium and after pregnancy.
Sections du résumé
BACKGROUND
BACKGROUND
It has been suggested that women experiencing during pregnancy several physiological and immunological changes that might increase the risk of any infection including the SARS-CoV-2.
OBJECTIVE
OBJECTIVE
We aimed to quantify the risk of SARS-CoV-2 infection during pregnancy compared with women with no pregnancies.
METHODS
METHODS
We used data from the BIFAP database and a published algorithm to identify all pregnancies during 2020. Pregnancies were matched (1:4) by age region, and length of pregnancy with a cohort of women of childbearing age. All women with SARS-CoV-2 infection before entering the study were discarded. We estimated incidence rates of SARS-CoV-2 with 95% confidence intervals (CIs) expressed by 1000 person-months as well as Kaplan-Meier figures overall and also stratified according to pregnancy period: during pregnancy, at puerperium (from end of pregnancy up to 42 days) and after pregnancy. (from 43 days after pregnancy up to end pf study period (i.e., June 2021). We conducted a Cox regression to assess risk factors for SARS-COV infection. The incidence rate of SARS-CoV-2 infection expressed by 1000 person-months were.
RESULTS
RESULTS
There was a total of 103,185 pregnancies and 412,740 matched women at childbearing, with a mean age of 32.3 years. The corresponding incidence rates of SARS-CoV-2 infection according to cohorts were: 2.44 cases per 1000 person-months (confidence interval (CI) 95%: 2.40-2.50) and 4.29 (95% CI: 4.15-4.43) for comparison cohort. The incidence rate ratio (IRR) of SARS-CoV-2 was 1.76 (95% CI: 1.69-1.83). When analyzing according to pregnancy period, the IRRs were 1.30 (95% CI: 11.20-1.41) during the puerperium and 1.19 (95% CI: 41.15-1.23) after pregnancy. In addition to pregnancy itself, other important risk factors were obesity (1.33 (95% CI: 1.23-1.44)) and diabetes (1.23 (95% CI: 11.00-1.50).
CONCLUSION
CONCLUSIONS
Pregnant women are at increased risk of SARS-CoV-2 infection compared with women of childbearing age not pregnant. Nevertheless, there is a trend towards reverting during puerperium and after pregnancy.
Identifiants
pubmed: 36553953
pii: healthcare10122429
doi: 10.3390/healthcare10122429
pmc: PMC9777798
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1641-1647
pubmed: 33151921
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1269-1278
pubmed: 34015159
Am J Obstet Gynecol. 2020 Jul;223(1):135
pubmed: 32333857
Am J Obstet Gynecol. 2020 Aug;223(2):284-286
pubmed: 32348743
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1236-1245
pubmed: 32337840
Am J Obstet Gynecol. 2020 Nov;223(5):764-768
pubmed: 32730899
Rev Med Virol. 2021 Sep;31(5):1-16
pubmed: 33387448
Clin Epidemiol. 2018 Jun 05;10:643-654
pubmed: 29892204
Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):209-216
pubmed: 30548462
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Am J Obstet Gynecol MFM. 2020 May;2(2):100107
pubmed: 32292902
Am J Obstet Gynecol. 2021 Jul;225(1):75.e1-75.e16
pubmed: 33607103
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
CMAJ. 2021 Apr 19;193(16):E540-E548
pubmed: 33741725
Am J Obstet Gynecol. 2020 Aug;223(2):296-297
pubmed: 32387327
Am J Reprod Immunol. 2015 Mar;73(3):199-213
pubmed: 25582523
Am J Reprod Immunol. 2020 Nov;84(5):e13306
pubmed: 32779810
Viruses. 2020 Feb 10;12(2):
pubmed: 32050635
Cureus. 2022 Mar 6;14(3):e22900
pubmed: 35265437
Clin Microbiol Infect. 2021 Jan;27(1):36-46
pubmed: 33148440
Brain Behav. 2020 Nov;10(11):e01835
pubmed: 32969190
Am J Obstet Gynecol. 2012 Oct;207(4):288.e1-7
pubmed: 23021691
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):769-775
pubmed: 32584795
JAMA Netw Open. 2021 Jan 4;4(1):e2036462
pubmed: 33512520
PLoS One. 2021 Aug 11;16(8):e0255994
pubmed: 34379700
Ultrasound Obstet Gynecol. 2020 May;55(5):700-708
pubmed: 32160345
Crit Care Med. 2005 Oct;33(10 Suppl):S390-7
pubmed: 16215363
Diabetes Care. 2015 Jul;38(7):1356-64
pubmed: 25877811
Int J Equity Health. 2020 Jul 29;19(1):126
pubmed: 32727486
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Physiol Rev. 2021 Jan 1;101(1):303-318
pubmed: 32969772
Pharmacoepidemiol Drug Saf. 2020 Jan;29(1):57-68
pubmed: 31749191
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Lancet. 2020 Feb 22;395(10224):e40
pubmed: 32035511